NEW YORK, Sept. 4, 2012 /PRNewswire/ -- Harwood Feffer LLP ( www.hfesq.com) is investigating potential claims against the board of directors of Medicis Pharmaceutical Corp. ("Medicis" or the "Company") (NYSE: MRX) concerning the proposed acquisition of the Company by Valeant Pharmaceuticals International Inc. ("Valeant") in a transaction valued at approximately $2.6 billion.
On September 4, 2012, it was announced that Medicis and Valeant have entered into a definitive agreement pursuant to which Valeant will purchase Medicis. Under the agreement, Medicis shareholders will receive $44.00 in cash per share held.
Our investigation concerns whether the Medicis board of directors is fulfilling its fiduciary duties, maximizing the value of the Company, disclosing all material benefits and costs, and obtaining full and fair consideration for Company shareholders.If you own Medicis shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact: Matthew Houston, Esq. Benjamin Sachs-Michaels, Esq. Christopher Safrath Harwood Feffer LLP 488 Madison Avenue New York, New York 10022 Phone Numbers: (877) 935-7400 (212) 935-7400 Email: email@example.com Website: http://www.hfesq.com Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website ( http://www.hfesq.com) for more information about the firm. Attorney Advertising.© 2012 Harwood Feffer LLP. The law firm responsible for this advertisement is Harwood Feffer LLP ( www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. SOURCE Harwood Feffer LLP
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts